RxSight (RXST) Asset Writedowns and Impairment (2020 - 2026)
RxSight's (RXST) quarterly Asset Writedowns and Impairment came in at $1.1 million in Q2 2026, down 8.45% on a YoY basis from $1.2 million in Q2 2025, and up 1760.0% quarter-over-quarter from $60000.0 in Q1 2026.
Powered by 
Analysis
RxSight (RXST) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
RxSight (RXST) has reported Asset Writedowns and Impairment for 7 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Asset Writedowns and Impairment fell 8.45% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 million (up 24.95% YoY), and the FY2025 full-year result was $1.9 million, up 378.22% from the prior year.
- Asset Writedowns and Impairment grew to $1.1 million in Q2 2026 per RXST's latest filing, from $60000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.2 million in Q2 2025 and bottomed at -$1000.0 in Q3 2023.
- Historically, Asset Writedowns and Impairment has averaged $246000.0 across 5 years, with a median of $72000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment slumped 100.3% in 2023, then soared 16700.0% in 2024.
- Over 5 years, Asset Writedowns and Impairment stood at $298000.0 in 2022, then plunged by 49.33% to $151000.0 in 2023, then plunged by 52.98% to $71000.0 in 2024, then soared by 767.61% to $616000.0 in 2025, then surged by 81.17% to $1.1 million in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $1.1 million, $60000.0, and $616000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | RxSight | 265.13 Mn | -139.12 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Mn |
| Mar 31, 2026 | 60,000.00 |
| Dec 31, 2025 | 616,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 31,000.00 |
| Dec 31, 2024 | 71,000.00 |
| Sep 30, 2024 | 166,000.00 |
| Jun 30, 2024 | 56,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | 10,000.00 |
| Dec 31, 2022 | 298,000.00 |
| Sep 30, 2022 | 334,000.00 |
| Jun 30, 2022 | 47,000.00 |
| Mar 31, 2022 | 73,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | 608,000.00 |